The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer
Official Title:
Study ID: NCT03008343
Brief Summary: The aim of this study is the safety and efficacy of irreversible electroporation (IRE) plus natural killer (NK) immunotherapy to recurrent liver cancer.
Detailed Description: By enrolling patients with recurrent liver cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using IRE and NK cells. The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).
Minimum Age: 30 Years
Eligible Ages: ADULT
Sex: ALL
Healthy Volunteers: No
Fuda cancer institute of Fuda cancer hospital, Guangzhou, Guangdong, China